Bristol-Myers, Otsuka slapped with Abilify suit; Roche said to drop idea of Chugai bid;

Pharma News

@FiercePharma: Top-read over the weekend: Pfizer eyes Actavis in backup plan to another AstraZeneca bid. More | Follow @FiercePharma

@TracyStaton: Novo Nordisk CEO on the house that Victoza built and the future of diabetes R&D. Article via FierceBiotech | Follow @TracyStaton

@EricPFierce: As EvaluatePharma figures, 2014 could rival 2009 in M&A action, and that is a lot. More | Follow @EricPFierce

@CarlyHFierce: ICYMI: Valeant, Ackman pass threshold to call pivotal Allergan meeting. Story | Follow @CarlyHFierce

> Bristol-Myers ($BMY) and its Abilify partner Otsuka were sued in New York by a patient claiming that the companies failed to properly warn doctors that the antipsychotic hikes the risk of diabetes in children. Report

> Roche ($RHHBY), which announced an $8.6 billion deal for InterMune ($ITMN) over the weekend, is said to have decided against bidding for the share of Japan's Chugai that it doesn't already own. Report

> India's government put all state-owned hospitals under review for "systemic corruption," including gifts from drugmakers designed to promote prescribing of their products. Report

> China's Luye Pharmaceutical minted a new billionaire--its chairman, Liu Dianbo--after strong first-half results sent its stock soaring. Report

> Since President Obama railed against companies looking for tax-inversion deals, such as Pfizer ($PFE) with its AstraZeneca ($AZN) bid, no companies have announced a buyout that relies on this sort of tax savings. Report

> Argentina, a key Latin American market for pharma, has added Indian drugmakers to its list of approved suppliers. Report

Medical Device News

@FierceMedDev: ICYMI:  approves more innovative med tech, faster in first half. Story | Follow @FierceMedDev

@VarunSaxena2: Covidien acquisition of Reverse Medical illustrates vascular device focus. Article | Follow @VarunSaxena2

@EmilyWFierce: $MDT shareholders rail against company's pending merger with $COV. Story via Pioneer Press | Follow @EmilyWFierce

> Chinese physicians implant first 3-D printed vertebrae in child. Story

> Endo reported to be selling its AMS med-dev unit. Article

> FDA approves more innovative med tech, faster in first half. More

Biotech News

@FierceBiotech: Roche extends biotech shopping spree with $8.3B InterMune buyout. News | Follow @FierceBiotech

@JohnCFierce: Getting the feeling today that the slower summer news cycle is coming to a close. | Follow @JohnCFierce

@EmilyMFierce: ICYMI: UCSF spinout launches crowdfunding campaign for Ebola drug. Story | Follow @EmilyMFierce

> Allergic reactions force Regado to pull the plug on PhIII anticoagulant study. Story

> J&J snaps up Covagen and its protein-antibody fusion platform. News

> Merck and Advaxis forge another no-money-down IO development pact. Article

CRO News

> Quintiles and Illumina look to jump-start cancer R&D with genomics sweepstakes. Article

> Evotec teams up with malaria nonprofit in open R&D project. Report

> Parexel: Biotech's boom pays dividends for CROs. More

> CRO PharPoint signs up to get Otologic's hearing drug into the clinic. Story

> Clinverse reels in a $9.1M funding round to expand its trial tech. Article

Biotech IT News

> Illumina teams with AstraZeneca, J&J and Sanofi on cancer diagnostic. More

> Rollout of openFDA continues with drug labeling, medtech adverse event APIs. Article

> Clinverse and Comprehend raise $30M in separate financing rounds. More

> uBiome raises $4.5M as first batch of Y Combinator biotechs pitch to investors. Story

> Rock Health backs cloud-based R&D platform as Abbott comes on board. Article

Animal Health News

> Merck releases tilapia vaccine. News

> China's Skystar Bio-Pharmaceutical sees revenue grow 25%. Report

> FDA warns Kentucky drug compounder after sick, dead horses reported. Article

> Boehringer Ingelheim's Vetmedica to open $30M facility near Kansas City. Story

> Kinavet CA-1 moves forward to trials. Item

And Finally... Medical advances have taken a bite out of the blood-products business, as the need for transfusions has declined by almost one-third over the past 5 years. Report